Loading organizations...
Loading organizations...
20/20 Gene Systems is a Rockville, Maryland-based biotechnology company that develops and commercializes machine learning-powered laboratory blood tests for early cancer detection and personalized therapies. The clinical diagnostics firm operates a certified laboratory to process proprietary screening panels, including its flagship OneTest multi-cancer early detection product, which it sells to consumers, healthcare providers, and employers. Operating with approximately 18 employees, the company has raised over 9.7 million dollars in prior capital to fund its diagnostic research and commercialization efforts. The enterprise experienced significant expansion recently, recording 600 percent revenue growth in fiscal year 2021 and ranking 131st on the 2022 Inc magazine list of fastest-growing companies. 20/20 Gene Systems is backed by institutional investors such as Ping An Ventures and has utilized retail equity crowdfunding platforms including StartEngine and Wefunder to secure additional financing. The organization was founded in 2000 by Jonathan Cohen.
20/20 Gene Systems has raised $6.5M across 2 funding rounds.
20/20 Gene Systems has raised $6.5M in total across 2 funding rounds.
20/20 Gene Systems has raised $6.5M in total across 2 funding rounds.
20/20 Gene Systems's investors include Jiang Zhang, Keiretsu Capital.
20/20 GeneSystems, Inc. is a Rockville, Maryland-based digital diagnostics company focused on reducing cancer mortality worldwide through early detection technologies, leveraging machine learning and real-world data to modernize clinical lab testing.[1][2] Its flagship product, OneTest, is a multi-cancer blood test screening for at least five cancer types from a single sample, alongside past COVID-19 solutions like PCR viral tests, rapid antibody, and antigen tests.[1][4] The company serves patients, healthcare providers, and global markets—primarily the US and Asia—addressing the critical problem of late-stage cancer detection by enabling earlier, non-invasive screening to improve survival rates.[2][3] As a Reg A+ private corporation, it has raised over $5 million via equity crowdfunding, marking it as one of the most successful in life sciences, with ongoing opportunities for accredited investors, family offices, and VCs.[2]
Founded by Jonathan Cohen (CEO), 20/20 GeneSystems draws on deep expertise in cancer biomarkers, with Michael S. Lebowitz, PhD as Chief Scientific Officer and Jiming Zhou, PhD as COO.[3] Dr. Zhou's background includes academic research on lung cancer at the University of Iowa, leading a $330 million pharmaceutical project, directing clinical labs, co-founding companies, and publishing 20+ papers with multiple patents, bridging US and Chinese healthcare.[3] The idea emerged from years of experience developing cancer biomarker tests, evolving into a mission-driven focus on AI-powered blood tests for early detection amid rising global cancer burdens.[2][3] Early traction includes successful crowdfunding exceeding $5 million and global operations, with pivotal SEC filings validating its multi-cancer screening approach.[2][4]
20/20 GeneSystems rides the liquid biopsy and AI diagnostics wave, capitalizing on trends in precision medicine where early cancer detection via blood tests could slash mortality by enabling interventions before symptoms.[1][2] Timing aligns with post-COVID demand for rapid, scalable testing and aging populations driving cancer rates, plus Asia's booming healthcare markets.[2][3] Favorable forces include regulatory progress (e.g., SEC Reg A+ enabling broad funding) and falling sequencing/AI costs, positioning it against giants like Grail while influencing ecosystems through biomarker advancements and US-China collaborations.[2][3][4] It democratizes access, boosting startup agility in medtech via crowdfunding and real-world data integration.
Next steps likely involve OneTest commercialization, clinical expansions, and partnerships in US/Asia to scale adoption, building on $5M+ funding for trials and regulatory wins.[2] Trends like AI-enhanced multi-omics and global cancer screening mandates will propel growth, potentially evolving 20/20 into a diagnostics leader via acquisitions or IPO paths. Its crowd-funded model could amplify influence, inspiring accessible biotech innovation and tying back to its core: modernizing labs to save lives through early detection.[1][2]
20/20 Gene Systems has raised $6.5M across 2 funding rounds. Most recently, it raised $4.5M Series A in January 2016.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Jan 14, 2016 | $4.5M Series A | Jiang Zhang | |
| Aug 1, 2015 | $2.0M Series A | Keiretsu Capital |